Evidence Medical Technologies LLC Mansfield, TX - 76063

Evidence Medical Technologies LLC is categorized under Electromedical Equipment in Mansfield, TX and active since 2010.

Evidence Medical Technologies LLC was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Electromedical Equipment business, which does work in the B2B market, and is classified as a Electromedical Equipment, under code number 334510 by the NAICS.

If you are seeking more information, feel free to contact Karen Clum at the company’s single location by writing to 1208 Lake Meadow Drive, Mansfield, Texas TX 76063 or by phoning (404) 630-1365. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Evidence Medical Technologies LLC
Contact Person: Karen Clum
Address: 1208 Lake Meadow Drive, Mansfield, Texas 76063
Phone Number: (404) 630-1365
Annual Revenue (USD): $100.000 to $499.999
Founded: 2010
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Electromedical Equipment
SIC Code: 3845
NAICS Code: 334510
Share This Business:

Evidence Medical Technologies LLC was started in 2010 to provide professional Electromedical Equipment under the SIC code 3845 and NAICS code 334510. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact Karen Clum for inquiries that concern Evidence Medical Technologies LLC by calling the company number (404) 630-1365, as your correspondence is most welcome. Additionally, the physical location of the single location of Evidence Medical Technologies LLC can be found at the coordinates 32.599192,-97.123997 as well as the street address 1208 Lake Meadow Drive in Mansfield, Texas 76063.

For its online presence, you may visit Evidence Medical Technologies LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.